ASTM F2100-26 Takes Effect, Impacts Structural Epoxy Exports to US Medtech

On May 1, 2026, the updated ASTM F2100-26 standard for medical face masks entered into force in the United States. While formally scoped to surgical and procedure masks, its newly introduced requirements on epoxy-based material biocompatibility (per ISO 10993-5 and ISO 10993-10) and extractable substance migration limits are now being applied by the U.S. FDA’s review divisions to structural adhesive components used in medical device assembly. Exporters of structural epoxy adhesives from China supplying U.S.-based medical device manufacturers must therefore address this shift — particularly those engaged with facilities under FDA-regulated quality systems.

Event Overview

The ASTM F2100-26 standard became effective on May 1, 2026. It includes revised testing criteria for biocompatibility of polymer substrates and adhesives in contact with biological tissues or fluids, referencing ISO 10993-5 (cytotoxicity) and ISO 10993-10 (irritation and sensitization). Although the standard itself applies to medical masks, the U.S. FDA has indicated — through recent premarket review practices — that these biocompatibility expectations extend to structural epoxy components used in Class I, II, and III medical device manufacturing. Exporters must now provide dual-certification test data aligned with both NSF/ANSI 51 (for food equipment materials) and ISO 10993 series standards; absence of such documentation may result in customs delays or rejection at U.S. receiving facilities.

Industries Affected

Direct Exporters of Structural Epoxy Adhesives

These companies supply formulated epoxy systems to U.S. medical device assemblers. They are directly impacted because their product specifications — previously validated only for mechanical performance and shelf life — now require supplemental biocompatibility evidence. Impact manifests in delayed order fulfillment, increased pre-shipment verification burden, and potential contract renegotiation if existing formulations lack supporting ISO 10993 data.

Raw Material Suppliers to Epoxy Formulators

Suppliers of epoxy resins, hardeners, or additives (e.g., accelerators, fillers) may face upstream requests for ISO 10993-compliant grade declarations or full extractables profiling. Their impact is indirect but operationally significant: formulation traceability and raw material lot-level biocompatibility documentation are now part of downstream compliance chains.

Contract Manufacturers & Device Assemblers (U.S.-based)

U.S. medical device firms sourcing structural epoxy adhesives from Chinese suppliers must verify conformance before integrating them into production. Failure to do so risks nonconformance during FDA inspections or audit findings related to supplier controls (21 CFR Part 820.50). The impact lies in extended incoming inspection cycles and potential requalification of legacy adhesive processes.

Logistics & Regulatory Support Providers

Firms offering customs brokerage, regulatory consulting, or test lab coordination services for medical device supply chains are seeing increased demand for NSF/ANSI 51 + ISO 10993 test package management. Their role shifts toward facilitating cross-standard documentation alignment — not just for masks, but for ancillary bonding materials entering FDA-regulated environments.

Key Focus Areas and Recommended Actions

Monitor official FDA communications on adhesive-related guidance

While ASTM F2100-26 does not explicitly regulate adhesives, the FDA’s application of its biocompatibility clauses remains interpretive. Companies should track FDA’s Center for Devices and Radiological Health (CDRH) updates, especially any forthcoming draft guidance referencing ISO 10993 applicability to non-device components.

Identify high-risk adhesive applications in current export portfolios

Not all structural epoxy uses trigger ISO 10993 requirements. Priority should be given to adhesives used in devices with direct or indirect tissue contact (e.g., housing seals on infusion pumps, sensor mounting in wearable monitors, or bonding layers in sterilizable instrument trays). Adhesives used solely for mechanical assembly of non-contact housings may remain outside scope — pending further clarification.

Distinguish between policy signal and enforceable requirement

Analysis shows that FDA’s current enforcement reflects a risk-based review trend rather than a codified regulation. It is not yet embedded in 21 CFR or formal FDA guidance documents. Therefore, while documentation gaps pose real operational risk, they do not yet constitute a statutory violation absent an adverse event or inspection finding.

Initiate dual-test protocol planning with accredited labs

NSF/ANSI 51 and ISO 10993 testing involve distinct protocols and timelines. Companies should confirm lab capacity for combined testing (e.g., cytotoxicity per ISO 10993-5 alongside food-contact migration per NSF/ANSI 51 Annex A), allocate budget for sample preparation and extraction studies, and align internal technical files with ISO 13485-compliant documentation structures.

Editorial Perspective / Industry Observation

Observably, ASTM F2100-26’s implementation signals a broader regulatory convergence: biocompatibility expectations originally developed for finished devices are increasingly cascading down to enabling materials — even those not classified as medical devices themselves. This is not yet a formal rule change, but rather a de facto quality expectation emerging from FDA review practice. From an industry perspective, it reflects tightening scrutiny over material safety in the context of device reliability and patient safety. Current relevance lies less in immediate legal obligation and more in supply chain readiness: firms that treat this as a procedural update rather than a strategic quality milestone may encounter friction in customer onboarding or post-market surveillance.

Conclusion
This development underscores how standards updates in one medical product category can ripple across adjacent supply chain tiers — especially where material safety intersects with regulatory oversight. It is best understood not as a standalone compliance mandate, but as an early indicator of evolving FDA expectations for material traceability and biological safety in medical device manufacturing ecosystems. For exporters and suppliers, proactive alignment with ISO 10993 and NSF/ANSI 51 evidentiary frameworks — grounded in actual use-case risk assessment — represents the most pragmatic path forward.

Source Attribution
Main source: ASTM International (ASTM F2100-26 Standard Specification for Performance of Materials Used in Medical Face Masks); U.S. FDA Center for Devices and Radiological Health (CDRH) premarket review patterns observed in Q1–Q2 2026.
Note: Ongoing observation is recommended regarding whether FDA issues formal guidance or updates 21 CFR Part 820 language to reflect this expanded interpretation of biocompatibility requirements for structural adhesives.